Home » News » Awards & Advancement » Creabilis names Moukheibir to board of directors

Creabilis names Moukheibir to board of directors

Thursday, February 28, 2013

Creabilis, a late clinical stage European biotechnology company specializing in developing treatments in dermatology, inflammation and pain, has appointed Catherine Moukheibir to its board of directors.

Catherine has more than 30 years of experience in the pharmaceutical industry and finance. Currently, she is senior advisor, finance and a member of the executive committee at Innate Pharma, where she was responsible for a key licensing deal with Bristol-Myers Squibb. Previously, she was CFO at Movetis, where she played a major role in the company’s IPO and subsequent acquisition by Shire. She also has held senior roles in investment banking at Morgan Stanley and Salomon Smith Barney.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!